Medical tech company Masimo (NASDAQ: MASI) will be reporting earnings this Tuesday afternoon. Here’s what investors should know.
Masimo beat analysts’ revenue expectations by 1.1% last quarter, reporting revenues of $372 million, up 9.5% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ constant currency revenue estimates but a significant miss of analysts’ full-year EPS guidance estimates.
Is Masimo a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Masimo’s revenue to grow 7.2% year on year to $368.7 million, a reversal from the 24.5% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.22 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Masimo has missed Wall Street’s revenue estimates six times over the last two years.
Looking at Masimo’s peers in the patient monitoring segment, some have already reported their Q2 results, giving us a hint as to what we can expect. iRhythm delivered year-on-year revenue growth of 26.1%, beating analysts’ expectations by 7.3%, and DexCom reported revenues up 15.2%, topping estimates by 2.8%. iRhythm traded up 17.6% following the results while DexCom was down 9.3%.
Read our full analysis of iRhythm’s results here and DexCom’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the patient monitoring stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Masimo is down 3.3% during the same time and is heading into earnings with an average analyst price target of $184.43 (compared to the current share price of $157.02).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
